Thus, a genomic analysis needs to be performed in this study to determine the impact of genomic alterations (such as mutations in the exonuclease domain of the DNA polymerase epsilon (POLE), high tumor mutational burden, and the presence of biallelic loss of CDK12, among others) on immunotherapy for PCa, for the early detection and identification of novel therapeutic targets. The gene discussed is CDK12; the disease is neoplasm.